Glibenclamide reduced the rate of lesion growth in BALB/c mice infected with Leishmania (Leishmania) mexicana, the effect was dose dependent, and the highest dose proved more effective than glucantime. Cross-resistance to glucantime was found in animals infected with a glibenclamide-resistant line, but combined therapy reduced lesion progression even in the glibenclamide-resistant strain.
No takes yet. Share an insight, caveat, or question.
Serrano-Martín et al. (2006) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: